ELIQUIS_PPT_Template_V1jz

Slides:



Advertisements
Similar presentations
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Advertisements

New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Atrial Fibrillation Service
AF and the New Oral Anti-Coagulants
DURNER L.,BOURDOUMIS A., MASOOD J., BUCHHOLZ N. ROYAL LONDON HOSPITAL, BARTSHEALTH NHS TRUST ROYAL DEVON AND EXETER NHS TRUST HOMERTON UNIVERSITIY HOSPITAL.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Project Objective To enhance the system of care for atrial fibrillation that not only reduces system costs, but improves the experiences of both patients.
CLINICAL CASES.
Post oral surgery bleeding for adult patients receiving antithrombotic therapy.
ARISTOTLE TRIAL Dr R Nyabadza GPST1 Ward 32. Structure AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the.
Too Close for Comfort? For How Long Must I Stop This Anticoagulant For an Epidural? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
AF and NOACs An UPDATE JULY 2014
APIXABAN NELLA SPAF 21 maggio 2015 ROMA Dott. Sergio Agosti Cardiologo, Ospedale Novi Ligure (AL)
Atrial Fibrillation Warfarin and its newer alternatives
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines Antiplatelet Therapy for Vascular Prevention in Patients with.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Atrial Fibrillation Current Management Strategies.
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert.
Secondary Prevention Following Coronary Artery Bypass Grafting: are we Compliant with the Guidelines? V. Joshi, B. Bridgewater University Hospital of South.
1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 
Massachusetts Medical Society, Health Policy/Health Systems 1 Warfarin Survey November 2007.
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Update in ESC: Dabigatran among OAC
Case study – patient presenting with newly diagnosed NVAF Full Prescribing Information is provided at the end of this presentation NVAF: non-valvular atrial.
Case study - patient presenting with newly diagnosed NVAF with prior CAD Full Prescribing Information is provided at the end of this presentation EUAPI581k;
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
ANTICOAGULATION The objectives of this section are: To be able to write prescriptions according to local anticoagulation guidelines To know how to prescribe.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
ELIQUIS_PPT_Template_V1jz
Managing AF in Patients with Complex Comorbidities and Over the Long Term
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Managing AF in Patients with Complex Comorbidities and Over the Long Term
Management of Patients on Chronic Oral Anticoagulant Therapy
Update on the Watchman Device CRT 2010 Washington, DC
CRT 2017: Putting LAA closure in the age of DOACs into perspective
When should aspirin be dropped from triple therapy?
Exploring Factors Associated with Preferential Prescribing of Apixaban Over Warfarin in Patients with Non-Valvular Atrial Fibrillation Scott McColgana,
How Do We Incorporate Patient Perspectives Into Clinical Trial Design?
An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
Managing AF in Patients with Complex Comorbidities and Over the Long Term
Department of Cardiology Bern University Hospital
Evolving anticoagulation in primary care
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Anticoagulation Prepared by Cherie Gan.
Click here for title Click here for subtitle
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Access to NOAC Therapy:
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Fibrillazione atriale
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
NOACS: Emerging data in ACS/IHD
Access to NOAC Therapy:
Adherence in SPAF: Measures to Improve Care
Example Patient Journeys
Bridging Anticoagulation
What oral antiplatelet therapy would you choose?
Erratum Canadian Journal of Cardiology
Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;
Figure 8. Stroke prevention strategy in patients with AF
Case 5 Revision surgery after pertrochanteric fracture
Presentation transcript:

ELIQUIS_PPT_Template_V1jz 4/11/2018 2:13:06 PM https://www.polleverywhere.com/free_text_polls/wn5ThHkQNasXfbv

Common Challenges of Anticoagulation Management ELIQUIS_PPT_Template_V1jz 4/11/2018 2:13:06 PM Common Challenges of Anticoagulation Management

Disclaimer Bristol-Myers Squibb and Pfizer abide by the Medicines Australia Code of Conduct and our own internal policies, and as such, will not engage in the promotion of unregistered products or unapproved indications. The statements, conclusions and opinions contained in the following presentations are those of the presenter and do not necessarily reflect those of the sponsor Bristol-Myers Squibb or Pfizer. Please refer to the appropriate approved Product Information before prescribing any agents mentioned in this presentation. The Product Information is available through the BMS Australia and Pfizer Australia websites, the trade display or from your BMS or Pfizer representative. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, Level 2, 4 Nexus Court, Mulgrave, VIC, Australia. Pfizer Australia Pty Ltd, ABN 50 008 422 348 38-42 Wharf Road, West Ryde, NSW, AUSTRALIA. 432AU1600448-07. PP-ELI-ANZ-0030

ELIQUIS_PPT_Template_V1jz 4/11/2018 2:13:06 PM https://www.polleverywhere.com/free_text_polls/wn5ThHkQNasXfbv

Cases Cessation of anticoagulation in a patient with an intracerebral bleed Peri-operative management and bridging of anticoagulation Patient switched to aspirin presents with a stroke Elderly patient with multiple co-morbidities Warfarin patient requiring multiple procedures Warfarin-stable patient

81 year old falls off mobility scooter, develops intracerebral bleed Case 1 81 year old falls off mobility scooter, develops intracerebral bleed History Non-valvular atrial fibrillation (NVAF), diabetic, excess alcohol, major compliance issues Initially commenced on warfarin 5 years ago, INR fluctuating between 1.2  and 4.0 Serious fall from mobility scooter resulting in an intracerebral bleed Warfarin ceased as perceived falls risk; health improved and alcohol consumption decreased Recommenced on NOAC (rivaroxaban) 2yrs ago via Webster Pak and daily nurse supervision Episode of severe peri-rectal bleeding dropping Hb to 90; colonoscopy not done due to comorbidities Now off all anticoagulants

ELIQUIS_PPT_Template_V1jz 4/11/2018 2:13:06 PM https://www.polleverywhere.com/multiple_choice_polls/lei3ZMsZBEN1OWy

Return to Main Menu Discussion Case 1 81-year-old falls off mobility scooter, develops intracerebral bleed Audience discussion Falls are associated with increased mortality in AF. But there is no evidence that patients at high risk of falls are at increased risk of major bleeds.1,2 How do you currently manage AF patients requiring anticoagulation that are at falls risk? Discussion Reference Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962. Banerjee A, Clementy N, Haguenoer K et al. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Am J Med 2014; 127: 972-8. https://www.polleverywhere.com/free_text_polls/wn5ThHkQNasXfbv Return to Main Menu Reference: 1. Kirchhof P et al. Eur Heart J 2016; 37: 2893-962. Banerjee A et al. Am J Med 2014; 127: 972-8.

80-year-old on NOAC requiring surgery Case 2 80-year-old on NOAC requiring surgery History 80-year-old male, chronic NVAF well controlled on apixaban Prostate obstructive symptoms, booked for transurethral resection of the prostate (TURP) NOAC ceased 48 hours pre-operatively, uneventful procedure. Day 2 post op, had small cerebral infarction Day 3 had arterial embolus in the left leg treated with embolectomy and fasciotomy in city Returns home on warfarin from major teaching hospital; no reason why this was the choice of anticoagulant

Comments on this course of action? Case 2 80 year old on NOAC requiring surgery Audience discussion Do we switch him back to a NOAC? Comments on this course of action? Return to Main Menu

Patient on aspirin presenting with stroke Case 3 Patient on aspirin presenting with stroke 68 year old female, CHA2DS2VASc = 2 Admitted to Emergency Department with non-valvular AF and congestive cardiac failure (CCF) Apixaban 5mg BD started Cardiologist switched to aspirin Subsequent admission with stroke

ELIQUIS_PPT_Template_V1jz 4/11/2018 2:13:06 PM https://www.polleverywhere.com/multiple_choice_polls/hNBcbKc2r0CpaiQ

Return to Main Menu Discussion Case 3 Patient on aspirin presenting with stroke Audience discussion Do we switch AF patients on aspirin to an OAC? Discussion https://www.polleverywhere.com/free_text_polls/wn5ThHkQNasXfbv Return to Main Menu

Elderly patient with co-morbidities Case 4 Elderly patient with co-morbidities 84 year old hypertensive, very active male in NVAF In discussion with treating physician for >10 years regarding the potential benefit of anticoagulant, but patient not impressed with being on "rat poison" and needing monthly blood tests/finger pricks NOACs became available, he is convinced to commence apixaban Reviewed 1 month later, all ok Reviewed another 2 months later, had ceased apixaban as 2 episodes of epistaxis Patient unable to be convinced that he should recommence his NOAC

Return to Main Menu Discussion Case 4 Elderly patient with co-morbidities Audience discussion How do we manage an AF patient that refuses any anticoagulation? Discussion Return to Main Menu

74-year-old on warfarin requiring multiple procedures Case 5 74-year-old on warfarin requiring multiple procedures History 74-year-old male, paroxysmal non-valvular AF and pacemaker for conversion pauses, on warfarin Elective admission for permanent pacemaker (PPM) generator change. Stopped warfarin 7 days prior, heparin bridging when INR < 2. Surgery delayed due to a cardiothoracic surgery emergency Post-operative heparin infusion until INR > 2. Hematoma, discharged 8 days post admission Subsequent infection ~3 months later, device extracted. New device implanted Warfarin & bridging resulted in time in hospital and complications

Return to Main Menu Discussion Case 5 Patient on warfarin requiring multiple procedures Audience discussion OAC interruptions should be minimised to prevent stroke.1 Are we bridging NOAC patients undergoing cardiovascular interventions that could be performed safely on continued therapy? Discussion Reference 1. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962. Return to Main Menu Reference: 1. Kirchhof P et al. Eur Heart J 2016; 37: 2893-962.

70-year-old warfarin-stable patient Case 6 70-year-old warfarin-stable patient History 70-year-old male (farmer), paroxysmal non-valvular AF, on warfarin CHA2DS2VASc = 3; monthly INRs are stable Complained of not being able to have his green leafy vegetables from his own garden when in season – issue of dietary restriction Switched to NOAC (apixaban) No problems

Return to Main Menu Discussion Case 6 Stable warfarin patient Audience discussion According to the 2016 European Society of Cardiology (ESC) guidelines for the management of AF, a NOAC is recommended in preference to a vitamin K antagonist for patients eligible for anticoagulation1 . When should we consider switching a warfarin-stable patient to a NOAC? Discussion Reference 1. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962. Return to Main Menu Reference: 1. Kirchhof P et al. Eur Heart J 2016; 37: 2893-962.

ELIQUIS_PPT_Template_V1jz 4/11/2018 2:13:06 PM https://www.polleverywhere.com/free_text_polls/wn5ThHkQNasXfbv

End of presentation